Description
Palmitoylethanolamide is an endogenous cannabinoid. It is a weak ligand of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors. It has been found to inhibit FAAH (fatty acid amide hydrolase). Palmitoylethanolamide exhibits anti-nociceptive, anti-inflammatory, anti-convulsant and immunosuppresant activity. Palmitoylethanolamide acts by binding to an unidentified cannabinoid receptor that is similar to CB2. It also acts as a selective activator of the GPR55 receptor. In addition, this compound directly activates PPARα, producing an anti-inflammatory response.An endogenous cannabinoid agonist, FAAH inhibitor, and PPARα agonist